Review for Disease of the Year: Treatment of Viral Anterior Uveitis: A Perspective.

Zandi, Souska; Bodaghi, Bahram; Garweg, Justus G. (2018). Review for Disease of the Year: Treatment of Viral Anterior Uveitis: A Perspective. Ocular immunology and inflammation, 26(7), pp. 1135-1142. Informa Healthcare 10.1080/09273948.2018.1498109

Full text not available from this repository. (Request a copy)

PURPOSE To define a clinically tailored therapeutic strategy for the treatment of viral anterior uveitis (VAU). METHODS A PubMed search spanning the past 5 years was conducted using the MesH-terms "viral anterior uveitis" and "therapy." RESULTS The herpes simplex virus (HSV), the varicella zoster virus (VZV), and the cytomegalovirus (CMV) are the predominant pathogens in VAU. Other viruses, including rubella, chikungunya, and zika, have been linked with distinct forms of the disease. Depending on the causative agent and the host immunocompetence, the mainstay treatment for suspected VAU is a combination of topical or systemic antivirals and topical corticosteroids, supplemented with cycloplegics and intraocular-pressure-lowering medication. CONCLUSIONS Oral acyclovir, valacyclovir, and famciclovir are the mainstay of treatment for HSV- and VZV-induced infections. Brivudin serves as an alternative in insufficiently responsive cases. CMV-induced infections respond well to valganciclovir. A 3- to 12-month course of prophylactic treatment against recurrences is worth considering.

Item Type:

Journal Article (Review Article)


04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Ophthalmology

UniBE Contributor:

Garweg, Justus


600 Technology > 610 Medicine & health




Informa Healthcare




Sebastian Wolf

Date Deposited:

04 Dec 2018 11:31

Last Modified:

04 Dec 2018 11:31

Publisher DOI:


PubMed ID:


Uncontrolled Keywords:

Acyclovir antivirals treatment valacyclovir viral anterior uveitis


Actions (login required)

Edit item Edit item
Provide Feedback